長期投資家のためのIR情報
 バリュートレンド
  1. HOME
  2. バリュートレンド
  3. 【4549】栄研化学

【4549】栄研化学
検査薬。
類似企業：
【業界1位】 小野薬品工業
【売上同水準】 扶桑薬品工業 JCRファーマ


東証プライム
医薬
＞
医他
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
決算期 日付 予・実 売上高
(百万円)		 対前回 修正率 修正率 営業利益
(百万円)		 対前回 修正率 修正率 経常利益
(百万円)		 対前回 修正率 修正率 当期利益
(百万円)		 対前回 修正率 修正率
2027.03 2026/07/30 Q1予 42,000 → 0.0% 0.0% 3,070 → 0.0% 0.0% 2,900 → 0.0% 0.0% 2,070 → 0.0% 0.0%
2027.03 2026/05/12 当初予 42,000 - - - 3,070 - - - 2,900 - - - 2,070 - - -
2026.03 2026/05/12 実 41,899 ↓ -0.7% -0.7% 2,919 ↓ -10.2% -10.2% 2,844 ↓ -8.3% -8.3% 3,708 ↓ -1.6% -1.6%
2026.03 2026/01/30 Q3予 42,200 → 0.0% 0.0% 3,250 → 0.0% 0.0% 3,100 → 0.0% 0.0% 3,770 → 0.0% 0.0%
2026.03 2025/10/30 Q2予 42,200 → 0.0% 0.0% 3,250 → 0.0% 0.0% 3,100 → 0.0% 0.0% 3,770 → 0.0% 0.0%
2026.03 2025/07/31 Q1予 42,200 → 0.0% 0.0% 3,250 → 0.0% 0.0% 3,100 → 0.0% 0.0% 3,770 → 0.0% 0.0%
2026.03 2025/05/13 当初予 42,200 - - - 3,250 - - - 3,100 - - - 3,770 - - -
2025.03 2025/05/13 実 40,539 ↑ +0.8% -5.9% 2,999 ↓ -6.6% -47.0% 3,198 ↓ -2.2% -43.1% 2,228 ↓ -15.0% -50.3%
2025.03 2025/01/31 Q3予 40,200 → 0.0% -6.7% 3,210 → 0.0% -43.3% 3,270 → 0.0% -41.8% 2,620 → 0.0% -41.5%
2025.03 2024/10/31 Q2予 40,200 ↓ -6.7% -6.7% 3,210 ↓ -43.3% -43.3% 3,270 ↓ -41.8% -41.8% 2,620 ↓ -41.5% -41.5%
2025.03 2024/07/31 Q1予 43,100 → 0.0% 0.0% 5,660 → 0.0% 0.0% 5,620 → 0.0% 0.0% 4,480 → 0.0% 0.0%
2025.03 2024/05/09 当初予 43,100 - - - 5,660 - - - 5,620 - - - 4,480 - - -
2024.03 2024/05/09 実 40,052 ↓ -1.1% -4.6% 3,377 ↓ -16.4% -37.2% 3,568 ↓ -13.6% -33.9% 2,634 ↓ -13.4% -38.0%
2024.03 2024/01/30 Q3予 40,500 ↓ -3.6% -3.6% 4,040 ↓ -24.9% -24.9% 4,130 ↓ -23.5% -23.5% 3,040 ↓ -28.5% -28.5%
2024.03 2023/10/26 Q2予 42,000 → 0.0% 0.0% 5,380 → 0.0% 0.0% 5,400 → 0.0% 0.0% 4,250 → 0.0% 0.0%
2024.03 2023/07/28 Q1予 42,000 → 0.0% 0.0% 5,380 → 0.0% 0.0% 5,400 → 0.0% 0.0% 4,250 → 0.0% 0.0%
2024.03 2023/04/28 当初予 42,000 - - - 5,380 - - - 5,400 - - - 4,250 - - -
2023.03 2023/04/28 実 43,271 ↓ -0.8% +8.2% 7,457 ↓ -0.2% +64.3% 7,568 ↑ +0.5% +65.6% 5,736 ↓ -1.1% +58.9%
2023.03 2023/01/30 Q3予 43,600 → 0.0% +9.0% 7,470 → 0.0% +64.5% 7,530 → 0.0% +64.8% 5,800 → 0.0% +60.7%
2023.03 2022/10/27 Q2予 43,600 → 0.0% +9.0% 7,470 → 0.0% +64.5% 7,530 → 0.0% +64.8% 5,800 → 0.0% +60.7%
2023.03 2022/09/20 修正予 43,600 ↑ +9.0% +9.0% 7,470 ↑ +64.5% +64.5% 7,530 ↑ +64.8% +64.8% 5,800 ↑ +60.7% +60.7%
2023.03 2022/07/26 Q1予 40,000 → 0.0% 0.0% 4,540 → 0.0% 0.0% 4,570 → 0.0% 0.0% 3,610 → 0.0% 0.0%
2023.03 2022/04/28 当初予 40,000 - - - 4,540 - - - 4,570 - - - 3,610 - - -
2022.03 2022/04/28 実 42,996 ↑ +6.4% +6.4% 8,387 ↑ +31.7% +31.7% 8,508 ↑ +32.3% +32.3% 6,218 ↑ +26.6% +26.6%
2022.03 2022/01/28 Q3予 40,400 → 0.0% 0.0% 6,370 → 0.0% 0.0% 6,430 → 0.0% 0.0% 4,910 → 0.0% 0.0%
2022.03 2021/10/27 Q2予 40,400 → 0.0% 0.0% 6,370 → 0.0% 0.0% 6,430 → 0.0% 0.0% 4,910 → 0.0% 0.0%
2022.03 2021/07/26 Q1予 40,400 → 0.0% 0.0% 6,370 → 0.0% 0.0% 6,430 → 0.0% 0.0% 4,910 → 0.0% 0.0%
2022.03 2021/04/28 当初予 40,400 - - - 6,370 - - - 6,430 - - - 4,910 - - -
2021.03 2021/04/28 実 38,667 ↑ +4.2% +13.4% 6,612 ↑ +19.4% +61.3% 6,808 ↑ +20.1% +62.1% 5,044 ↑ +17.0% +52.8%
2021.03 2021/01/27 Q3予 37,100 ↑ +8.8% +8.8% 5,540 ↑ +35.1% +35.1% 5,670 ↑ +35.0% +35.0% 4,310 ↑ +30.6% +30.6%
2021.03 2020/10/26 当初予 34,100 - - - 4,100 - - - 4,200 - - - 3,300 - - -
2020.03 2020/04/28 実 36,585 ↓ -0.6% +1.9% 4,622 ↑ +6.3% +28.4% 4,723 ↑ +6.1% +29.4% 3,538 ↑ +4.1% +36.1%
2020.03 2020/01/28 修正予 36,800 ↑ +2.5% +2.5% 4,350 ↑ +20.8% +20.8% 4,450 ↑ +21.9% +21.9% 3,400 ↑ +30.8% +30.8%
2020.03 2019/10/25 Q2予 35,900 → 0.0% 0.0% 3,600 → 0.0% 0.0% 3,650 → 0.0% 0.0% 2,600 → 0.0% 0.0%
2020.03 2019/07/24 Q1予 35,900 → 0.0% 0.0% 3,600 → 0.0% 0.0% 3,650 → 0.0% 0.0% 2,600 → 0.0% 0.0%
2020.03 2019/04/25 当初予 35,900 - - - 3,600 - - - 3,650 - - - 2,600 - - -
2019.03 2019/04/25 実 35,761 ↓ -2.7% -2.7% 4,611 ↑ +9.8% +9.8% 4,681 ↑ +10.7% +10.7% 3,447 ↑ +13.4% +13.4%
2019.03 2019/01/29 Q3予 36,760 → 0.0% 0.0% 4,200 → 0.0% 0.0% 4,230 → 0.0% 0.0% 3,040 → 0.0% 0.0%
2019.03 2018/10/23 Q2予 36,760 → 0.0% 0.0% 4,200 → 0.0% 0.0% 4,230 → 0.0% 0.0% 3,040 → 0.0% 0.0%
2019.03 2018/07/25 Q1予 36,760 → 0.0% 0.0% 4,200 → 0.0% 0.0% 4,230 → 0.0% 0.0% 3,040 → 0.0% 0.0%
2019.03 2018/04/27 当初予 36,760 - - - 4,200 - - - 4,230 - - - 3,040 - - -
2018.03 2018/04/27 実 34,991 ↓ -2.4% -2.4% 3,478 ↑ +13.3% +13.3% 3,549 ↑ +15.6% +15.6% 2,608 ↑ +19.6% +19.6%
2018.03 2018/01/26 Q3予 35,840 → 0.0% 0.0% 3,070 → 0.0% 0.0% 3,070 → 0.0% 0.0% 2,180 → 0.0% 0.0%
2018.03 2017/10/24 Q2予 35,840 → 0.0% 0.0% 3,070 → 0.0% 0.0% 3,070 → 0.0% 0.0% 2,180 → 0.0% 0.0%
2018.03 2017/07/26 Q1予 35,840 → 0.0% 0.0% 3,070 → 0.0% 0.0% 3,070 → 0.0% 0.0% 2,180 → 0.0% 0.0%
2018.03 2017/04/27 当初予 35,840 - - - 3,070 - - - 3,070 - - - 2,180 - - -
2017.03 2017/04/27 実 33,274 ↓ -1.6% -1.6% 3,976 ↑ +46.7% +46.7% 4,112 ↑ +51.7% +51.7% 2,918 ↑ +60.3% +60.3%
2017.03 2017/01/26 Q3予 33,830 → 0.0% 0.0% 2,710 → 0.0% 0.0% 2,710 → 0.0% 0.0% 1,820 → 0.0% 0.0%
2017.03 2016/04/27 当初予 33,830 - - - 2,710 - - - 2,710 - - - 1,820 - - -
2016.03 2016/04/27 実 32,163 ↓ -2.0% -2.0% 3,536 ↑ +6.2% +6.2% 3,570 ↑ +6.6% +6.6% 2,429 ↑ +11.4% +11.4%
2016.03 2016/01/26 Q3予 32,820 → 0.0% 0.0% 3,330 → 0.0% 0.0% 3,350 → 0.0% 0.0% 2,180 → 0.0% 0.0%
2016.03 2015/10/23 Q2予 32,820 → 0.0% 0.0% 3,330 → 0.0% 0.0% 3,350 → 0.0% 0.0% 2,180 → 0.0% 0.0%
2016.03 2015/07/24 Q1予 32,820 → 0.0% 0.0% 3,330 - - - 3,350 → 0.0% 0.0% 2,180 → 0.0% 0.0%
2016.03 2015/04/27 当初予 32,820 - - - - - - - 3,350 - - - 2,180 - - -
2015.03 2015/04/27 実 - - - - - - - - - - - - - - - -
2015.03 2015/01/27 Q3予 31,320 → 0.0% 0.0% 2,900 → 0.0% 0.0% 2,930 → 0.0% 0.0% 1,870 → 0.0% 0.0%
2015.03 2014/10/23 Q2予 31,320 → 0.0% 0.0% 2,900 → 0.0% 0.0% 2,930 → 0.0% 0.0% 1,870 → 0.0% 0.0%
2015.03 2014/07/24 Q1予 31,320 → 0.0% 0.0% 2,900 → 0.0% 0.0% 2,930 → 0.0% 0.0% 1,870 → 0.0% 0.0%
2015.03 2014/04/28 当初予 31,320 - - - 2,900 - - - 2,930 - - - 1,870 - - -
2014.03 2014/04/28 実 30,027 - - - 3,008 - - - 3,095 - - - 1,984 - - -
シェア ツイート
ページトップへ戻る